MGMT and central nervous system cancer: Additionally, we explored the mRNA expression of PANoRGs across various clinical and molecular phenotypes—including grade, histology, IDH mutation status, 1p19q codeletion, and MGMT promoter methylation—in the TCGA-Glioma cohort (Supplement Fig. 1) and CGGA-Glioma cohort (Supplement Fig. 2), revealing noticeable heterogeneity in the transcriptional levels of most PANoRGs across glioma samples.